US Markets

S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation

Credit: REUTERS/KIM HONG-JI

South Korea's Celltrion Inc said on Monday it has received emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates.

SEOUL, Oct 26 (Reuters) - South Korea's Celltrion Inc 068270.KS said on Monday it has received emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates.

Celltrion said Sampinute delivers coronavirus test results within 10 minutes, with a sensitivity of around 94%.

The authorisation came three months after requesting approval in late July and the product has already been launched in the United States in August, according to the company statement.

"(The company) is planning to supply Sampinute across the United States through local wholesalers as it believes the demand for rapid diagnosis kits will be high, mainly among large businesses and government agencies that are about to return to work after telecommuting," it said in a statement.

Shares of Celltrion Inc surged as much as 4.6%, while Celltrion Pharm 068760.KQ and Celltrion Healthcare 091990.KQ jumped 4.6% and 1.6%, respectively. Broader KOSPI .KS11, however, was trading down 0.1% as of 0208 GMT.

(Reporting by Joori Roh; Editing by Kim Coghill)

((joori.roh@thomsonreuters.com; +82 2 6936 1493;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More